• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA panel to discuss Immunomedics agent

Article

A Food and Drug Administration advisory committee is set to meetFeb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agentfor colorectal cancer developed by Immunomedics. Immunomedics,of Morris Plains, NJ, has been working with the FDA on the

A Food and Drug Administration advisory committee is set to meet

Feb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agent

for colorectal cancer developed by Immunomedics. Immunomedics,

of Morris Plains, NJ, has been working with the FDA on the agent's

product license application (PLA) since the agency said the PLA

was not approvable in 1994 (SCAN 6/1/94).

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.